Answers are grounded in this paper and cite their sources.
Five inhibitors of the NS5a enzyme have been approved as part of oral regimens for the treatment of hepatitis C virus, including daclatasvir (Bristol-Myers Squibb), ledipasvir (Gilead Sciences), ombitasvir (AbbVie), elbasvir (Merck), and velpatasvir (Gilead Sciences). This article reviews worldwide patents and patent applications that have been published on synthetic routes and final forms for these five drugs.
No takes yet. Share an insight, caveat, or question.
David L. Hughes (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: